Short answer
LENSAR, Inc. (LNSR) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $12M (down 2.6% year over year) with net income of −$5M.
Q3 2026 key financials · XBRL
- Revenue
- $12M
- −2.6% YoY · −15.6% QoQ
- Net income
- −$5M
- −27.2% YoY · −233.6% QoQ
- Operating margin
- -11.5%
- EPS (diluted)
- −$0.05
- +82.8% YoY · −108.2% QoQ
Source: XBRL data from the LENSAR, Inc. (LNSR) Q3 2026 10-Q on SEC EDGAR. USD.
LENSAR, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $14.1M, down 1% YoY from $14.3M, driven by lower System sales offset by higher procedure volume
- Product revenue $10.7M, down 6%; procedure revenue $9.2M, up 17% from $7.8M
- Gross margin 57.8% vs 42.1% YoY, based on revenue and cost of revenue
- Net loss $4.7M vs $3.7M; Adjusted EBITDA $1.7M vs $(0.3)M
- Operating cash outflow $5.3M vs $15.4M; $10.0M revolving facility established, undrawn at quarter-end; tariff inflation remains a headwind
Risk Factors
- New legal risk, triggered by terminated Alcon merger: additional shareholder demands or litigation could increase costs and result in damages
- Most material update, merger termination: distributor activity declined after announcement, with further production and inventory impacts expected
- Regulatory risk, EU Medical Devices Regulation: CE-mark compliance required before selling products in EU member states
- Competitive risk, Bausch + Lomb SeeLyra™: second-generation femtosecond laser expected to launch in the second half of 2026
- Financial risk, credit facility: $3.0 million minimum cash requirement until 2026 EBITDA covenant compliance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LENSAR, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.